| Literature DB >> 27885498 |
Ayako Chida1,2, Kei Inai2, Hiroki Sato3, Eriko Shimada2, Tsutomu Nishizawa4, Mitsuyo Shimada2, Michiko Furutani2, Yoshiyuki Furutani2, Yoichi Kawamura1, Masaya Sugimoto5, Jun Ishihara6, Masako Fujiwara7, Takashi Soga8, Masatoshi Kawana9, Shinya Fuji10, Shigeru Tateno11, Kenji Kuraishi12, Shigetoyo Kogaki13, Mitsuhiro Nishimura14, Mamoru Ayusawa15, Fukiko Ichida16, Hirokuni Yamazawa17, Rumiko Matsuoka4,18, Shigeaki Nonoyama1, Toshio Nakanishi19.
Abstract
Although some studies have attempted to find useful prognostic factors in hypertrophic cardiomyopathy (HCM), those results are not fully helpful for use in actual clinical practice. Furthermore, several genetic abnormalities associated with HCM have been identified. However, the genotype-phenotype correlation in HCM remains to be elucidated. Here, we attempted to assess patients with different types of gene mutations causing HCM and investigate the prognosis. A total of 140 patients with HCM underwent a screening test for myofilament gene mutations by direct sequencing of eight sarcomeric genes. Patients with a single mutation in cardiac troponin T, cardiac troponin I, α-tropomyosin, and regulatory and essential light chains were excluded from the study because the number of cases was too small. The clinical presentations and outcomes of the remaining 127 patients with HCM, 31 β-myosin heavy chain (MYH7) mutation carriers, 19 cardiac myosin-binding protein C (MYBPC3) mutation carriers, and 77 mutation non-carriers were analyzed retrospectively. MYBPC3 mutation carriers had a high frequency of ventricular arrhythmia and syncope. Kaplan-Meier curves revealed no significant difference in prognosis among the three groups, but a lack of family history of sudden death (SD) and a past history of syncope were significantly related to poor prognosis. An absence of family history of SD and past history of syncope are useful prognostic factors in patients with HCM. MYH7 and MYBPC3 mutations did not significantly influence prognosis compared to non-carriers. However, patients with the MYBPC3 mutation should be closely followed for the possibility of SD.Entities:
Keywords: Gene mutation; Genotype–phenotype; HCM; Prognosis
Mesh:
Substances:
Year: 2016 PMID: 27885498 DOI: 10.1007/s00380-016-0920-0
Source DB: PubMed Journal: Heart Vessels ISSN: 0910-8327 Impact factor: 2.037